Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAmbre DeniniolleSVSophie VantyghemAFAude-Marie Fourmont

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 2-year survival of 64% in older patients with myeloid malignancies, suggesting allogeneic stem cell transplantation is viable despite nutritional and immune markers.

Key Points

  • Overall survival at 2 years was 64% for patients aged 70 and above with myeloid malignancies, indicating promising outcomes.
  • Progression-free survival and relapse incidence rates were 57% and 14% respectively, highlighting significant clinical implications for elderly transplants.
  • Assessment of nutritional status indicated only 1 patient with hypoalbuminemia, while elevated ferritin and fibrinogen levels were noted in a majority of patients.
  • The findings emphasize that pre-transplant immune deficiency and inflammatory status show no significant impact on transplantation outcomes for older patients.

Cite This Study

Deniniolle et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2dchttps://doi.org/10.1182/blood-2025-7785
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic Value of Geriatric Characteristics in Allogeneic Haematopoietic Stem Cell Transplant Recipients Aged Over 60 Years2025
  2. 2Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies2025 · 1 citations
  3. 3Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide2025
  4. 4Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age2025
  5. 5Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation2025